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Abstract
Hirschsprung disease (HSCR) is a congenital malformation characterized by the absence of enteric neurons in the distal part of
the colon. Several genes have been implicated in the development of this disease that together account for 20% of all cases,
implying thatother genes are involved.SinceHSCRisfrequently associated withothercongenitalmalformations, the functional
characterization of the proteins encoded by the genes involved in these syndromes can provide insights into the protein-
network involved in HSCR development. Recently, we found that KBP, encoded by the gene involved in a HSCR- associated
syndrome called Goldberg-Shprintzen syndrome, interacts with SCG10, a stathmin-like protein. To determine if SCG10 is
involved in the etiology of HSCR, we determined SCG10 expression levels during development and screened 85 HSCR patients
for SCG10mutations.Weshowed thatSCG10expressionincreasesduring developmentbut nogermline mutationwasfoundin
any of these patients. In conclusion, this study shows that SCG10 is not directly implicated in HSCR development. However, an
indirect involvement of SCG10 cannot be ruled out as this can be due to a secondary effect caused by its direct interactors.
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Introduction
Hirschsprung disease (HSCR) is an abnormality of the enteric
nervous system characterised by the lack of ganglia along a variable
length of the gut. It is a developmental disorder that arises due to
failure in migration of enteric neural crestcellsinto the intestinal tract
or due to a failure in survival, proliferation, or correct development of
enteric neurons once they reach the gut [1]. In either case an
aganglionic segment occurs in which contraction and relaxation is
absent. The length of the aganglionic segment can vary and HSCR
patients are classified into short segment (S-HSCR, 80%), long
segment (L-HSCR, 15%), or total colonic aganglionosis (TCA, 5%)
[2]. HSCRis a common genetic disorder with an estimated incidence
of 1:5000 live births and is more frequent in males than in females
(4:1), a difference most prominent in S-HSCR [3].
Several genes have been implicated in the development of this
disease, being RET the most important one [4]. RET (REarranged
during Transfection) encodes a receptor tyrosine kinase which is
expressed in neural crest derived lineages, playing a pivotal role
during development of the enteric nervous system [1]. Mutations in
the coding region of RET are responsible for 50% of familial HSCR
cases and 15% of sporadic ones [5]. However, they only account for
20% of all HSCR cases, suggesting that other genes are involved.
Since HSCR is frequently associated with other congenital
malformations present in rare recessive syndromes, the study of the
proteins involved in these syndromes can bring new insights about
HSCR development. Such syndrome, in which HSCR is frequently
observed, is Goldberg-Shprintzen syndrome (GOSHS), a rare
autosomal recessive disorder. The gene responsible for this syndrome
is KBP and recently we identified the Superior Cervical Ganglia
NeuralSpecific-10orSCG10asthemajorinteractingproteinofKBP
[6,7]. SCG10 is a stathmin-like protein involved in microtubule
dynamics [8]. But unlike other stathmins, SCG10 acts in two ways to
promote microtubule dynamics: it stabilizes microtubules at theirplus
end and promotes microtubule catastrophe at their minus end [9].
Moreover, SCG10 is known to play an important role in neuronal
differentiation by enhancing neurite outgrowth, a phenomenon that
is believed to be dependent on microtubule dynamics [8]. Also,
SCG10 has been previously identified as a down-regulated gene in a
RET mouse model for HSCR [10] and we have shown that SCG10
interacts with KBP in vitro and in vivo [7]. All together these facts
suggest that SCG10 might also play a role in HSCR development.
In this paper we evaluate the role of SCG10 in HSCR
development by determining SCG10 expression levels during the
process of gut colonization and by screening a set of isolated non-
syndromic HSCR patients without RET mutations for the
presence of SCG10 mutations.
Results
Expression of SCG10 in enteric neural crest stem cells
(ENCSCs)
To determine SCG10 involvement in the development of the
enteric nervous system, SCG10 expression levels were analysed in
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of mouse development, ENCSCs were isolated from E10.5 until
E15.5 mouse and maintained for 2 weeks in an undifferentiated
state. In these ENCSCs, SCG10 expression was detected in the
earliest stage analysed, E10.5, and an increase in expression levels
was observed in the following stages (Fig. 1). Our data shows that
there is an up-regulation of SCG10 expression levels in ENCSCs.
Mutation screening of SCG10
To further evaluate the involvement of SCG10 in HSCR
development, we screened blood DNA from 85 patients diagnosed
with isolated, non-syndromic HSCR. No germline mutation was
detected in SCG10.
Materials and Methods
Culture of ENCSCs
ENCSCs were prepared from embryonic gut (jejunum to
rectum) of C57BL/6 mice E10.5, 11.5, 12.5, 13.5, 14.5 and 15.5.
The gut was mechanically dissected and then tissues were incu-
bated in collagenase/dispase enzyme solution (collagenase XI
[750 U/ml; Sigma-Aldrich] and dispase II [250 mg/ml; Roche]) in
PBS for approximately 5 minutes at 37uC. Digested tissue was
triturated until a homogenous cell suspension was created. Cell
suspensions were washed and seeded on 35-mm petri dishes
previously coated with fibronectin (2 mg/cm
2, Sigma-Aldrich).
DMEM-F12 medium (PAA) containing N2 supplement (Invitro-
gen), B27-supplement (Invitrogen), 1% penicillin/streptomycin
(PAA), 20 ng/ml fibroblast growth factor (FGF, Peprotech) and
20 ng/ml epidermal growth factor (EGF, Peprotech), was used
as culture medium. Every two days half of the medium was
replaced with new medium containing freshly added FGF and
EGF. The enteric neural crest-derived cells were kept in culture as
neurospheres-like bodies (NLBs) for 14 days.
RNA extraction and RT-PCR
After 14 days in culture, NLBs were collected and washed with
PBS. RNA extraction was performed using the RNeasy mini kit

(Qiagen). First strand cDNA was originated from 2 ug of RNA
using the Ready-To-Go You-Prime First-Strand Beads
 kit (GE
Healthcare) and pdN[6] as first-strand primer. First-strand cDNA
generated by this method was directly used for RT-PCR. The
primers used for amplification were SCG10 forward (59-AC-
AATGGCTAAAACAGCAATGGC-39) and SCG10 reverse (59-
TGCTTCAGCCAGAC-39), Actin forward (59-ATATCGCTG-
CGCTGGTCGTC-39) and Actin reverse (59-AGGATGGCGT-
GAGGGAGAGC -39).
Patients
All patients included in this study were diagnosed with HSCR
disease and showed no mutations in the RET gene. All patients
included in this study gave their written informed consent. Ethical
approval was obtained from the UMCG ethical committee
(Medisch Ethische Toetsings commissie-UMCG). In total, 85
patients were screened. From these 85 patients 43 were S-HSCR,
11 were L-HSCR and for 31 cases the length of the segment
affected was unknown.
Mutation screening of SCG10
Genomic DNA was isolated from peripheral blood lymphocytes
by use of standard methods. Sequencing of exons 1-5 of SCG10
was performed using 5 sets of primers (for primers and PCR
conditions see table 1). DNA amplification was performed using
50 ng of genomic DNA in 30 ml PCR reactions containing: 10X
reaction buffer, 10 mM primer pair mix, 25 mM dNTPs and 1
unit Taq Polymerase (Amersham). PCR products were amplified
and purified (ExoSap it – GE Healthcare). Direct sequencing of
exons 1–5 was performed using the 3730 DNA Analyser (Applied
Biosystems). Using the software Mutation Surveyor (Version 3.23,
SoftGenetics LLC) sequences were aligned and compared with
consensus sequences.
Discussion
Hirschsprung disease (HSCR) is a developmental disorder in
which the process of gut colonization is disturbed. To date, 11
genes have been reported to be involved in HSCR development:
RET, GDNF, NTN, EDNRB, EDN3, SOX10, ECE-1, ZFHX1B,
PHOX2B, KBP and NRG1 [4,6,11–19]. However, all together, they
only explain approximately 20% of all HSCR cases. To better
understand HSCR development, the study of rare syndromes that
are characterized by the presence of HSCR can be of major
importance, as determining the protein network connected to the
mutated proteins can help identifying candidate genes. In this
study we focus on such a candidate gene, SCG10, encoding a
microtubule destabilizing protein, recently described to interact
with KBP and believed to be important in the development of
Goldberg-Shprintzen syndrome and consequently, in HSCR [7].
Furthermore, SCG10 has been previously identified as a down-
regulated gene in a RET mouse model for HSCR [10] reinforcing
the idea that SCG10 might also play a role in HSCR
development. Our results showed that SCG10 expression is
clearly up-regulated during the process of gut colonization, which
suggests that SCG10 migth play a role in the development of the
enteric nervous system. However, SCG10 screening in a set of
Figure 1. SCG10 expression levels during the development of
the enteric nervous system. Expression studies in mouse enteric
neural crest cells show that RNA levels of SCG10 are upregulated in the
initial stage of gut colonization [11.5] and remain constant until the
whole process is finished by E15.5.
doi:10.1371/journal.pone.0015144.g001
Table 1. PCR conditions.
Primer Sequences bp Size(bp)
Tm 6C
PCR Seq.prim
SCG10 1F TCTAGCACGGTCCCACTCTG 20 174 58 1F
SCG10 1R AGGTAGAGCCGACGGAGAAC 20
SCG10 2F ACCTGGCAATATTCACTCTG 20 340 58 2F
SCG10 2R TAGACACGGCAAGTCAATAG 20
SCG10 3F CTCCCGGAATAACAACGCTAC 21 444 58 3F
SCG10 3R ACATGTTGGCATGGCACAG 19
SCG10 4F CCGTTATTCTGCTAGGTTTG 20 327 58 4F
SCG10 4R TCAGGCATATGGAAGTTCAC 20
SCG10 5F TAGACACCAAACTGGGTTAC 17 236 58 5F
SCG10 5R ATCCTGATATCGCATGATCC 20
doi:10.1371/journal.pone.0015144.t001
SCG10 and Hirschsprung Disease
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e1514485 patients diagnosed with isolated, non-syndromic HSCR
showed that no mutation was present. Taken together, these
results suggest that although SCG10 seems necessary for the
development of the enteric nervous system, it is not directly
implicated in HSCR. A possible explanation for this result is that
SCG10 involvement in HSCR can be a consequence of a
disruption in the normal protein network necessary for proper
development. SCG10 activity is known to be controlled by two
post-translational modifications: palmitoylation and phosphoryla-
tion [20]. The first one is responsible for growth cone targeting of
SCG10 and the second one is responsible for controlling SCG10
activity. As RET is a tyrosine kinase receptor known to be involved
in several signalling pathways, it is possible that RET, via one of its
downstream pathways, controls SCG10 activity, linking this gene
directly to HSCR. Further studies are required to determine if
there is any association between RET and SCG10 and a possible
involvement of SCG10 in HSCR development.
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